Valeant Pharmaceuticals International Inc. has issued first quarter results that beat analyst estimates and boosted its 2015 estimates to account for about US$1 billion of additional revenue from Salix Pharmaceuticals. The Quebec-based company conducted a bidding war for Salix during the first quarter and closed the US$11.1-billion deal on April 1, which marked the beginning of its second quarter.